文献速递瓣膜外科冠心病外科

退行性二尖瓣病变合并冠心病患者瓣膜修复优于置换

Valve Repair Is Superior to Replacement in Most Patients With Coexisting Degenerative Mitral Valve and Coronary Artery Diseases.
PubMed 文献 · Ann Thorac Surg · 2016-12-06

该研究纳入1985至2011年1071例接受冠脉搭桥联合二尖瓣修复或置换的退行性二尖瓣反流成人患者,经倾向性匹配(177对)比较早期结局与远期生存。匹配后修复组住院死亡率、术后肾衰竭、再探查止血和呼吸衰竭均低于置换组,15年生存率修复组52% vs 置换组18%。结论认为修复可带来长期生存优势,应为首选。

要点

  • 退行性二尖瓣反流合并冠心病患者,二尖瓣修复较置换显著降低住院死亡率和术后并发症。
  • 匹配后修复组15年生存率52%,置换组仅18%。
  • 修复术后5年约18%患者仍有>3+二尖瓣反流,但瓣膜耐久性两组相似。

核心结论

  • 在退行性二尖瓣病变合并冠心病患者中,二尖瓣修复较置换预期可带来长期生存优势,尽管存在一定的二尖瓣反流复发。

研究设计与样本

  • 回顾性队列研究,1985至2011年共1071例成人(年龄70±9.3岁,77%男性)接受冠脉搭桥联合二尖瓣修复(n=872,81%)或置换(n=199,19%)。
  • 采用倾向性匹配(177对,覆盖89%可能匹配)比较早期结局及二尖瓣反流复发、再手术和死亡的时间相关事件。
  • 采用多变量多阶段风险函数分析识别死亡危险因素。

主要发现

  • 置换组患者年龄更大、瓣膜钙化更多、术前房颤和心衰患病率更高(均p<.0001)。
  • 匹配后置换组较修复组住院死亡率更高(5.0% vs 1.0%,p=.0001)。
  • 匹配后置换组术后肾衰竭(7.0% vs 3.2%,p=.01)、因出血再探查(6.0% vs 3.1%,p=.05)和呼吸衰竭(14% vs 4.7%,p<.0001)均更多。
  • 匹配后修复组5年时18%患者二尖瓣反流>3+;两组瓣膜耐久性相似。
  • 匹配后15年生存率置换组18%,修复组52%。

临床怎么用

  • 对退行性二尖瓣反流合并冠心病需同期手术的患者,只要解剖条件允许,应优先选择二尖瓣修复而非置换。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For mitral regurgitation (MR) from degenerative mitral disease in patients with coexisting coronary artery disease, the appropriate surgical strategy remains controversial. METHODS: From 1985 to 2011, 1,071 adults (age 70 ± 9.3 years, 77% men) underwent combined coronary artery bypass grafting and either mitral valve repair (n = 872, 81%) or replacement (n=199, 19%) for degenerative MR. Propensity matching (177 patient pairs, 89% of possible matches) was used to compare early outcomes and time-related recurrence of MR after mitral valve repair, mitral valve reoperation, and mortality. Risk factors for death were identified with multivariable, multiphase hazard-function analysis. RESULTS: Patients undergoing valve replacement were older, with more valve calcification and a higher prevalence of preoperative atrial fibrillation and heart failure (all p < .0001). Among matched pairs, mitral replacement versus repair was associated with higher hospital mortality (5.0% vs 1.0%, p = .0001) and more postoperative renal failure (7.0% vs 3.2%, p = .01), reexplorations for bleeding (6.0% vs 3.1%, p = .05), and respiratory failure (14% vs 4.7%, p < .0001). Of matched patients undergoing repair, 18% had MR above 3+ by 5 years. Mitral valve durability was similar between matched groups, but survival at 15 years was 18% after replacement versus 52% after repair. Nomograms from the multivariable equation revealed that in 94% of cases, 10-year survival was calculated to be higher after repair than after replacement. CONCLUSIONS: In patients with coexisting degenerative mitral valve and coronary artery diseases, mitral valve repair is expected to confer a long-term survival advantage over replacement despite some recurrence of MR. When feasible, it is the procedure of choice for these patients.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Javadikasgari H, Gillinov AM, Idrees JJ, et al. Valve Repair Is Superior to Replacement in Most Patients With Coexisting Degenerative Mitral Valve and Coronary Artery Diseases. Ann Thorac Surg. 2016. PMID: 27938885. doi:10.1016/j.athoracsur.2016.08.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。